Format

Send to

Choose Destination
Am J Surg. 2017 Aug;214(2):323-328. doi: 10.1016/j.amjsurg.2016.08.008. Epub 2016 Sep 2.

Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013.

Author information

1
Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
2
Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
3
Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA.
4
Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
5
Division of Health Services Research, Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, IA, USA. Electronic address: mary-schroeder@uiowa.edu.

Abstract

BACKGROUND:

Recent incidence, treatment patterns, and outcomes for node negative microscopically invasive breast cancer (MIBC) have not been reported.

METHODS:

State Health Registry of Iowa data identified women with ductal carcinoma in situ (DCIS), MIBC, and stage I breast cancer excluding MIBC (stage 1BC).

RESULTS:

From 2000 to 2013, 1,706, 193, and 4,514 women were diagnosed with DCIS, MIBC, and stage 1BC, respectively. MIBC increased at an annual percentage change of 2.1 (P = .041). MIBC was more frequently human epidermal growth factor receptor 2 positive than stage 1BC (39.7% vs 9.6%, P < .001). Mastectomy was performed more frequently in MIBC than DCIS (40.9% vs 30.6%, P = .014) or stage 1BC (40.9% vs 33.8%, P = .119). Chemotherapy was given to 4.1% of women with MIBC. Survival for women with MIBC was intermediate between DCIS and stage 1BC.

CONCLUSIONS:

Management of MIBC is an increasingly frequent clinical scenario. Women with MIBC receive more aggressive local and systemic therapy than women with DCIS.

KEYWORDS:

Breast neoplasms; Cancer incidence; Mastectomy; Microinvasive tumor; SEER program

PMID:
27692792
PMCID:
PMC5334458
DOI:
10.1016/j.amjsurg.2016.08.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center